TG Therapeutics (NASDAQ:TGTX) Given Hold (C-) Rating at Weiss Ratings

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “hold (c-)” rating reaffirmed by research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Other research analysts also recently issued reports about the stock. B. Riley lifted their target price on shares of TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 price objective on the stock in a research report on Thursday, July 10th. Finally, HC Wainwright initiated coverage on shares of TG Therapeutics in a research report on Monday. They set a “buy” rating and a $60.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $49.00.

TG Therapeutics Stock Performance

TG Therapeutics stock opened at $35.75 on Wednesday. The firm’s 50 day simple moving average is $31.55 and its 200-day simple moving average is $35.36. The company has a market cap of $5.67 billion, a P/E ratio of 96.62 and a beta of 1.97. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.86 and a quick ratio of 2.96. TG Therapeutics has a fifty-two week low of $21.27 and a fifty-two week high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analysts’ expectations of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The business’s revenue was up 92.1% on a year-over-year basis. During the same period last year, the business earned $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that TG Therapeutics will post 0.08 EPS for the current year.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares of the company’s stock, valued at $3,032,526.64. The trade was a 18.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 10.64% of the stock is owned by corporate insiders.

Institutional Trading of TG Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its stake in shares of TG Therapeutics by 1,809.9% in the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock worth $47,830,000 after buying an additional 1,149,526 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in shares of TG Therapeutics in the first quarter worth $30,545,000. Nuveen LLC acquired a new stake in shares of TG Therapeutics in the first quarter worth $29,442,000. Woodline Partners LP acquired a new stake in shares of TG Therapeutics in the first quarter worth $21,021,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of TG Therapeutics by 1,221.4% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 422,078 shares of the biopharmaceutical company’s stock worth $15,191,000 after buying an additional 390,137 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.